Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts but with combined complex I and IV deficiencies in muscle

H.A.C.M. Bentlage, MSc; U. Wendel, MD; H. Schägger, PhD; H.J. ter Laak, PhD; A.J.M. Janssen, BSc; and J.M.F. Trijbels, PhD

Article abstract—A 2-month-old boy died of a lethal infantile mitochondrial disease with severe lactic acidosis and involvement of the CNS. Histochemical analysis of skeletal muscle showed that cytochrome c oxidase staining was lacking in all muscle fibers but was present in arterioles. Ragged red fibers were not seen, but some fibers showed excessive staining for succinate dehydrogenase. Biochemical analysis revealed a combined complex I and IV deficiency in skeletal muscle but only a complex I deficiency in his fibroblasts. Two-dimensional native SDS electrophoresis confirmed these enzymatic findings at the protein level. Analysis of mitochondrial translation products in fibroblasts revealed no abnormalities, and analysis of mitochondrial DNA in muscle showed no depletion, large-scale deletions, or frequently occurring point mutations. We conclude that this disease must have been the result of either a nuclear DNA mutation in a gene controlling the expression or assembly of both complex I and the muscle-specific isoform of complex IV or, alternatively, a heteroplasmic point mutation in a mitochondrial tRNA, which codon is used more often by mtDNA encoded subunits of complex I than by mtDNA encoded subunits of complex IV. A different degree of heteroplasmy in skeletal muscle and fibroblasts would then explain the curious heterogeneous tissue expression of defects in this patient.

NEUROLOGY 1996;47:243-248

Mitochondrial encephalomyopathies are a heterogeneous group of disorders in which various tissues are affected, predominantly skeletal muscle and the CNS. The primary cause of disease is thought to be a defect in the mitochondrial energy metabolism. The five enzyme complexes (complexes I to V) of oxidative phosphorylation (OXPHOS) play a crucial role in this ATP-generating system. Each mitochondrion contains its own mitochondrial DNA (mtDNA), which is maternally inherited. The mtDNA encodes seven subunits of NADH:ubiquinone oxidoreductase (complex I), one subunit of ubiquinol:cytochrome c oxidoreductase (complex III), three subunits of cytochrome c oxidase (COX) (complex IV), two subunits of ATP synthase (complex V), two ribosomal RNAs, and 22 transfer RNAs necessary for mtDNA gene expression. The genes of complexes I, III, IV, and V are located in both the mtDNA and the nuclear DNA (nDNA). Succinate:ubiquinone oxidoreductase (complex II) contains only nDNA encoded subunits. All nDNA encoded subunits are imported into the mitochondria where they are assembled together with the mtDNA encoded subunits. Deficiencies in complex I and complex IV, either alone or combined, are found most frequently.

A growing number of mitochondrial encephalomyopathies or other neurologic disorders have been associated with deletions, depletions, or more than 30 point mutations in the mtDNA. These mutations are often found only in a proportion of the mtDNA molecules (heteroplasmy). Also, nDNA mutations affecting OXPHOS are expected to cause these diseases but have not been described so far.

We present a patient who immediately after birth had a severe lactic acidosis. Biochemical analysis revealed a combined deficiency of complex I and IV in muscle tissue but only an isolated complex I deficiency in fibroblasts.

Case report. A boy was born by normal delivery after an uncomplicated 39-week pregnancy. Birth weight was 3,680 g, length was 54.5 cm, and head circumference was 35 cm. His unrelated parents and a 4-year-old sister are in good health.

Within 18 hours after birth, the baby became tachypneic and developed an overwhelming lactic acidosis (blood pH 7.02, base excess —25.5 mmol/L, blood lactate 85 to 147 mg/dL [normal <16 mg/dL] and pyruvate 1.13 mg/dL [normal <0.59 mg/dL]). There were no signs of an infection. Plasma amino acid analysis revealed hyperalaninemia. Repeated urine analysis showed variable increased excretion of lactate, ethylmalonate, and 3-hydroxybutyrate. In CSF, lactate was elevated (42 mg/dL; normal 11 to 19 mg/dL).
Despite continuous buffering, severe acidotic periods re­
mant). and occasionally seizures occurred (signs of CNS involve­
curred. Gradually, a developmental delay, hypertonicity, 
and pyruvate was 3.52 mg/dL. Multivitamin therapy was 
Methods. 

Biochemical analysis of muscle tissue. The oxidation 
rates of radiolabeled substrates (pyruvate, malate, and 
succinate), the ATP + creatine phosphate (CrP) production 
rates from pyruvate and succinate, and the mitochondrial 
enzyme activities were measured in 600 g supernatant of 
muscle homogenates as described previously.8 Control 

Fibroblast studies. Human skin fibroblasts were 
grown in M199 (GIBCO) medium supplemented with 20% 
(f/v) fetal calf serum. Control specimens were obtained 
from healthy volunteers. Enzyme activities were measured 
in mitochondria-enriched fractions, which were prepared 
as described previously10 with the following modifications. 

Approximately 20 × 10⁶ cells were homogenized in 10 mM 
Tris·HCl (pH 7.6), thereafter adjusted to 0.25 M sucrose 
and subsequently differentially centrifuged (600 g and 
14,000 g). The formation of lactate and pyruvate from glu­
cose was determined in monolayer grown fibroblasts as 
described,11 except that fibroblasts were cultured in M199 
medium.

Two-dimensional electrophoresis. The amounts of as­
sembled OXPHOS enzymes in muscle homogenate (20 mg) 
or frozen fibroblasts (4 × 10⁶ cells) were quantitated by 
two-dimensional polyacrylamide gel electrophoresis (PAGE) 
(blue native/Tricine-SDS-PAGE) and subsequent 
densitometric analysis of Coomassie stained gels.9

Mitochondrial protein synthesis. Mitochondrial trans­
lation products of fibroblasts from the patient and two 
control subjects were labeled in near confluent six-well 
plates (diameter 1 cm) for 2 hours with [³⁵S]methionine 
(0.4 mCi/mL; 1,200 Ci/mmol) in the presence of emetine, 
an inhibitor of cytoplasmic protein synthesis, at 100 µg/ 

MtDNA analysis. MtDNA was analyzed in total DNA 
isolated from muscle as reported previously.16 The mtDNA 

Results. Histochemistry and electron microscopy. Morphologic examination of the patients skeletal muscle re­
vealed no ragged red fibers, but the staining for succinate 
dehydrogenase (SDH) showed a few large fibers with ex­
ceptionally high activity (figure 1, A and B). COX activity 
was absent in all muscle fibers but was present in smooth 
muscle cells of arterioles (figure 1, C and D). There was no 
glycogen or lipid accumulation. Electron microscopy re­
vealed no structural abnormalities of the mitochondria.

Biochemical studies. Biochemical investigation in fresh skeletal muscle 600 g supernatant revealed that oxida­
tion rates and ATP + CrP production rates with pyru­
vate, malate, and succinate as substrates were all signific­
antly diminished (p < 0.05; table 1). Complex IV activity 
was most severely decreased (11% of the mean of control 
subjects; p < 0.05). The activities of NADH:Q₁ oxidoreduc­
tase (complex I) was decreased 24% of the mean of control 
subjects and NADH:O₂ oxidoreductase (complexes I + III 
+ IV) were also decreased 27% of the mean of control 
subjects. Complex III and other enzyme activities were 
nearly normal (see table 1).

In the patient's fibroblasts, on the contrary, complex IV 
activity was in the normal range, both in whole cell homog­
enate and in the mitochondria enriched fraction (table 2). 
Here, only complex I activity was significantly decreased 
(39% of the mean of control subjects; p < 0.05). An in­
creased lactate-pyruvate ratio after glucose conversion in 
these cells (42, normal <25) pointed also toward a respira­
tory chain defect.

Two-dimensional electrophoresis. Analysis of muscle 

Homogenate of the patient fibroblasts revealed that all detectable 
mitochondrial translation products were present in amounts 
equal to two control subjects (figure 3). 

MtDNA analysis. Investigation of mtDNA in the patients 

muscle revealed no mtDNA depletion, large dele­
tions, or point mutations, which are frequently associated with 
mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes (MELAS, position 3243); myo­
clonic epilepsy and ragged red fiber disease (position

344 NEUROLOGY 47 July 1996
8344); and neurogenic weakness, ataxia, and retinitis pigmentosa (position 8993).7

Discussion. Our patient had a lethal infantile mitochondrial disease (LIMD)16 with lactic acidosis dominating the clinical presentation. Involvement of CNS pathology became apparent because of developmental delay, hypertonicity, an increased lactate level in CSF, and the occurrence of seizures. Other organs appeared normal.

Extensive biochemical analysis revealed the presence of a severe deficiency of both complex I and IV in skeletal muscle tissue but only of complex I in cultured skin fibroblasts. Other enzyme activities were not significantly decreased. These findings were confirmed by histochemical analysis of COX in muscle sections and by two-dimensional native SDS electrophoresis of all five OXPHOS enzymes in both muscle and fibroblasts.

Age differences between the patient (1 month at the time of muscle biopsy) and the control subjects (range 4 to 56 years, n = 28) are not relevant because the enzyme activities are normalized for CS activity.17

There are reports of two similar cases of LIMD with a combined deficiency of complex I and IV in muscle.18,19 Both patients suffered from muscular hypotonia and tachypnoea but not encephalopathy. The first patient died at 4 months old, and the combined deficiency was found in skeletal muscle, heart, and liver, but no deficiency was found in kidney and brain.18 Fibroblasts were not investigated. The authors postulated a nuclear DNA mutation in a developmental stage-specific and tissue-specific OXPHOS gene.18 The second patient died at the age of 53 days because of respiratory failure with lactic acidosis and had a combined defect in complexes I and IV in skeletal muscle mitochondria.19 We analyzed the respiratory chain enzymes in cultured fibroblasts of the latter patient and found no defect in complex I or IV (H.A.C.M.B., unpublished results). Both reported cases18,19 showed ragged red fibers in their muscle, whereas these were lacking in our patient. However, the excessive staining for SDH in some fibers could point toward the development of ragged red fibers in our patient. Thus, there are many clinical and biochemical similarities between the two reported cases and the one presented here. By contrast, the two reported cases18,19 had no apparent CNS involve-
Table 1 Biochemical measurements in fresh skeletal muscle

<table>
<thead>
<tr>
<th></th>
<th>Control Patients (%)* subjects† N</th>
<th>Oxidation rate (nmol/hr/mU CS)</th>
<th>[1-14C]Pyruvate + malate</th>
<th>0.60 (11) 5.52 ± 0.99 14 (3.61-7.48)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ATP + CrP production rate (nmol/hr/mU CS)</td>
<td>Pyruvate + malate</td>
<td>5.8 (9) 63.9 ± 10.1 16 (42.1-81.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Succinate + acetyl carnitine</td>
<td>5.3 (40) 13.1 ± 3.7 13 (7.2-18.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activity (mU/mU CS) NADH:Q1 oxidoreductase</td>
<td>0.036 (24) 0.153 ± 0.061 21 (0.061-0.276)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Succinate:cyanochrome c oxidoreductase</td>
<td>0.41 (78) 0.56 ± 0.13 26 (0.31-0.84)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Décylubiquinol:cyanochrome c oxidoreductase</td>
<td>2.78 (62) 4.52 ± 0.99 16 (2.85-6.61)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cyanochrome c oxidase</td>
<td>0.19 (11) 1.78 ± 0.61 28 (0.61-3.13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NADH:O2 oxidoreductase</td>
<td>0.12 (27) 0.44 ± 0.14 20 (0.28-0.84)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pyruvate dehydrogenase§</td>
<td>0.051 (63) 0.081 ± 0.024 25 (0.034-0.122)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CS (mU/mg protein)</td>
<td>67 (64) 104 ± 29 28 (65-162)</td>
</tr>
</tbody>
</table>

* Percent of mean of controls. † Values are means ± SD, range in parentheses. § In homogenate.

CS = citrate synthase.

Table 2 Enzyme activities* in mitochondria-enriched fractions of fibroblasts

<table>
<thead>
<tr>
<th></th>
<th>Control Patients (%)* subjects‡ N = 8</th>
<th>NADH:Q1 oxidoreductase</th>
<th>0.06 (39) 0.13 ± 0.03 0.10-0.20</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Succinate:cyanochrome c oxidoreductase</td>
<td>0.23 (94) 0.24 ± 0.04 0.20-0.31</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Décylubiquinol:cyanochrome c oxidoreductase</td>
<td>1.87 (98) 1.90 ± 0.31 1.56-2.61</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyanochrome c oxidase</td>
<td>0.78 (92) 0.85 ± 0.13 0.68-1.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytochrome c oxidase§</td>
<td>0.63 (91) 0.69 ± 0.11 0.54-0.89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CS (mU/mg protein)</td>
<td>203 (90) 226 ± 23 189-257</td>
</tr>
</tbody>
</table>

* Expressed in mU · mU−1 CS. † Percent of mean of controls. ‡ Values are means ± SD.

There are previous reports on heterogeneous tissue expression of OXPHOS defects in mitochondrial encephalomyopathies. In some cases, this was associated with mtDNA deletion or the MELAS 3243 mutation. Both mutations were excluded in our patient. We examined fibroblasts of 10 other patients with combined complex I and IV defects in muscle tissue, including some previously reported, and found only in one case a complex IV defect. All other fibroblasts did not show a respiratory chain enzyme defect. We demonstrated an isolated complex I deficiency also in fibroblasts of eight other patients, most of them having LIMD. All showed only a complex I deficiency in their muscle tissue (Bentlage, unpublished results). This illustrates the uniqueness of the case presented here.

Robinson et al. reported a complex I deficiency in fibroblasts of four patients with the clinical picture of LIMD. Three patients had signs of CNS involvement such as hypertonia, seizures, and an abnormal EEG. Unfortunately, they did not mention the biochemical investigation of muscle tissue; thus, it is unclear whether these patients also had a combined complex I and IV defect in their muscle.

A unique Chinese hamster mutant lung cell line, Gal 32, also exhibits extremely low activities of both complex I and IV at moderately decreased activities of other respiratory chain complexes. Simultaneous correction of this pleiotropic phenotype in a spontaneous revertant suggested the presence of a single nDNA mutation in Gal 32. Mitochondrial protein synthesis revealed low amounts of mtDNA encoded complex I and IV subunits in this cell line, whereas the amounts of mitochondrial RNAs were increased but of correct size. Therefore, a mutation altering mitochondrial tRNA structure or base modification was assumed. However, our patient had normal biosynthesis of all mitochondrial translation products in his fibroblasts, despite the reduced complex I activity. Thus, the phenotype of our patient probably arose from a different mutation.

In humans, there are tissue-specific isoforms of subunits VIa and VIIa of complex IV, a heart (H) and liver (L) form. In human heart, there are equal amounts of H- and L-forms, whereas in skeletal muscle there is mainly the H-form. The L-form is exclusively present in liver, brain, kidney, smooth muscle, and in cultured fibroblasts and myoblasts. During myogenesis and during fetal development, both subunits switch from L-type to H-type in human heart and skeletal muscle. Complex I possibly also has isoforms, but there are no data at the molecular level yet. A mutation in one of the H-type subunit isoforms of COX would account for the normal fetal development (L-form) and the heterogeneous tissue expression of the complex IV defect in the presented patient, that is, normal activity in...
arterioles (mainly smooth muscle) and fibroblasts (both L-form) and a deficiency in skeletal muscle (H-form). However, it does not explain the complex I defect in skeletal muscle and fibroblasts of the patient. A nuclear DNA mutation in a communal gene controlling both the expression or assembly of complex I and of the H-type isoenzyme of complex IV could explain the phenotype in our patient. Analysis of pet mutants in yeast identified several of such genes. A candidate gene could be the human homologue of the yeast gene oxa1, which is essential for COX assembly in yeast. However, there is no complex I in yeast; thus, the involvement of oxa1 in complex I expression remains to be established.

Alternatively, the pleiotropic defect and tissue heterogeneity can be explained by a point mutation in a mitochondriat rRNA and a different degree of heteroplasmy in muscle and fibroblasts, similar to patients with the 3243 MELAS mutation. Thus, the mutation must be in a mitochondrial tRNA whose codon is used more often by subunits of complex I than of IV and less by subunits of complexes III and V. Fibroblasts and cybrids with near homoplasmic point mutations at position 3260 and 3243 of the tRNALeu(UUR) gene (Bentlage and Attardi, unpublished results) can also exhibit a normal mitochondrial protein synthesis as is the case in our patients fibroblasts.

We are presently developing techniques to test both hypotheses in muscle tissue or fibroblasts of the presented case.

Acknowledgments
We thank Dr. E. van Oost (Department of Human Genetics) for the mtDNA analysis, Dr. W. Ruitenbeek (Department of Pediatrics) for critically reading the manuscript, Dr. F.J.M. Gabreëls (Department of Child Neurology) for advice, and Hoffman-La Roche, Basel, Switzerland for the gift of ubiquinone-1.

References


